secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001104659-25-050242
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma corporate deck touts bird flu TXM data, COVID plans, $15.9M cash
-----------------------------------------------------------------------------

- TXM bird flu: 100% survival in mice, dose-dependent survival in ferrets; single dose maintained plasma >EC90 for ~3 weeks in Phase 1.
- Pursuing FDA Animal Rule for bird flu; FDA meeting granted, briefing package submitted April 24, 2025.
- COVID candidate ratutrelvir: ritonavir-independent 10-day regimen; briefing document planned for June 2025.
- Cash $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.
- Legacy oncology assets (rigosertib, narazaciclib) remain; pursuing business development exit strategies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925050242/0001104659-25-050242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925050242/tm2515458d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-050242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer